CRSP
Crispr Therapeutics AG
54.00$
-5.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -48.0% | 21,776.2% | -18,487.8% | -17,759.6% | -142.9% | -6,236.6% | -12,766.8% | -9,520.1% | -10,712.2% | -7,468.9% | -1,889.7% | -3,572.9% | |
| – | 2.5% | 958.9% | 937.1% | 787.2% | 13.8% | 547.5% | 521.2% | 498.7% | 655.2% | 296.2% | 84.5% | 171.8% | |
| – | 9.2% | 3,850.2% | 4,578.7% | 3,578.6% | 62.7% | 2,336.6% | 1,973.9% | 1,867.7% | 2,092.1% | 1,119.6% | 330.4% | 632.0% | |
| – | -102.0% | 41,763.9% | 2,029.0% | -6,703.7% | -69.6% | 6,340.8% | -1,851.1% | 1,227.1% | 2,620.0% | -1,056.9% | -187.7% | -7.2% | |
| – | 0.4% | 143.1% | 136.8% | 36.4% | 0.7% | 23.8% | 13.1% | 8.3% | 59.8% | 34.6% | 11.3% | 16.8% | |
| – | -40.7% | -19,404.8% | -24,546.4% | -26,844.5% | 302.4% | -2,283.8% | 7,845.0% | -13,411.2% | 4,305.4% | -28,171.7% | -4,581.1% | -7,162.3% | |
| – | – | – | -90.1% | 77.4% | – | – | 7,988.0% | 8,015.0% | – | – | -7.1% | – | |
| – | 19.5% | 60,701.2% | -90.1% | 1,601.3% | 48.2% | 1,224.0% | 253.1% | 33,382.0% | 13,473.8% | 40,597.3% | 5,884.4% | 11,978.6% | |
| – | -69.1% | 63,070.4% | -43,124.0% | -42,990.4% | 207.4% | -7,291.7% | -4,659.8% | 10,447.6% | 7,067.2% | 4,699.6% | -586.7% | 1,215.1% | |
| – | -48.4% | 21,633.1% | -18,624.6% | -17,796.0% | -143.7% | -6,260.5% | -12,779.9% | -9,528.5% | -10,772.0% | -7,503.5% | -1,901.1% | -3,589.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.